恒瑞医药与 GSK 就 PDE3/4 抑制剂达成对外授权协议，进入全球呼吸竞争第一线。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 22,820 | 27,985 | 35,771 | 42,421 | 50,829 | | (+/-)% | 7.3% | 22.6% | 27.8% | 18.6% | 19.8% | | 净利润（归母） | 4,302 | 6,337 | 9,277 | 11,506 | 13,780 | | (+/-)% | 10.1% | 47.3% | 46.4% | 24.0% | 19.8% | | 每股净收益（元） | 0.65 | 0.96 | 1.40 | 1.74 | 2.09 | | 净资产收益率(%) | 10.6% | 13.9% | 17.9% | 19.1% | 19.6% | | 市盈率(现价&最新股本摊薄） | 83.03 | 56.38 | 38.51 | ...